Literature DB >> 7562787

Economic evaluation using mathematical models: the case of misoprostol prophylaxis.

S E Gabriel1.   

Abstract

Using misoprostol prophylaxis as an example, many of the methods employed in economic analyses that incorporate mathematical models were described. These included: decision analysis, cost effectiveness analysis (including incremental cost effectiveness analysis), one-way, multi-way, and probabilistic sensitivity analysis, and the estimation of quality adjusted life years for use in cost utility analysis. In the case of misoprostol prophylaxis, the cost effectiveness analysis demonstrated that, compared to the no prophylaxis alternative, prophylaxis cost an extra $650, on average, for every additional ulcer prevented, and was potentially cost saving for some high risk groups. The cost utility analysis demonstrated that prophylaxis resulted (on average) in modest additional costs and no additional quality of life benefits. Sensitivity analysis demonstrated that, at worst, prophylaxis reduced quality of life; at best, the incremental cost effectiveness ratio was $9333 for each quality adjusted life-year gained by prophylaxis compared to no prophylaxis. The results of the cost utility analysis also showed that prophylaxis may be cost saving in high risk groups, confirming the results of the cost effectiveness analysis. Finally, and perhaps most importantly, this analysis illustrated the importance of incorporating measures of health related quality of life into economic evaluation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562787

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.

Authors:  H E van Dieten; I B Korthals-de Bos; M W van Tulder; W F Lems; B A Dijkmans; M Boers
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

Review 2.  Economic evaluation of the management of pain in osteoarthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs. Implications of the MUCOSA trial.

Authors:  P J Davey; E Meyer
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.